Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $966000.0.

  • Coherus Oncology's Depreciation & Amortization (CF) fell 3763.72% to $966000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 2346.4%. This contributed to the annual value of $5.3 million for FY2024, which is 3917.17% up from last year.
  • Per Coherus Oncology's latest filing, its Depreciation & Amortization (CF) stood at $966000.0 for Q3 2025, which was down 3763.72% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Depreciation & Amortization (CF) registered a high of $1.5 million during Q3 2024, and its lowest value of $767000.0 during Q1 2022.
  • In the last 5 years, Coherus Oncology's Depreciation & Amortization (CF) had a median value of $949000.0 in 2023 and averaged $1.0 million.
  • Per our database at Business Quant, Coherus Oncology's Depreciation & Amortization (CF) soared by 7230.26% in 2024 and then plummeted by 3763.72% in 2025.
  • Coherus Oncology's Depreciation & Amortization (CF) (Quarter) stood at $836000.0 in 2021, then increased by 25.6% to $1.0 million in 2022, then grew by 1.24% to $1.1 million in 2023, then fell by 2.82% to $1.0 million in 2024, then dropped by 6.49% to $966000.0 in 2025.
  • Its last three reported values are $966000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.0 million during Q1 2025.